AMPH vs BAX
AMPH: Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging proprietary formulation and manufacturing capabilities to compete in high-margin, supply-constrained markets. BAX: A diversified healthcare company producing sterile IV solutions, infusion systems, parenteral nutrition, inhaled anesthetics, surgical sealants, smart beds, and patient monitoring systems for hospitals and home care globally.
Side-by-side fundamentals
| Metric | AMPH | BAX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $19.30 | $21.74 | |
| Market cap as of 2026-07-23 | $864M | $11.5B | |
| P/E as of 2026-07-23 | 10.90 | n/a | |
| PEG as of 2026-07-23 | -1.77 | -0.15 | AMPH lower |
| Net margin as of 2026-07-23 | +11.0% | -9.7% | AMPH higher |
| Gross margin as of 2026-07-23 | +47.3% | +30.7% | AMPH higher |
| Operating margin as of 2026-07-23 | +16.2% | -2.5% | AMPH higher |
| ROE as of 2026-07-23 | +10.2% | -16.4% | AMPH higher |
| ROA as of 2026-07-23 | +4.8% | -5.4% | AMPH higher |
| Debt / equity as of 2026-07-23 | 0.79 | 1.57 | AMPH lower |
| Revenue growth (YoY) as of 2026-07-23 | -1.4% | -4.8% | AMPH higher |
| Revenue CAGR (3y) SEC XBRL | +13.0% | +3.8% | AMPH higher |
| Dividend yield as of 2026-07-23 | n/a | +0.2% | |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-07-23 | 0.91 | 0.61 | |
| 1-year return as of 2026-07-22 close | -7.6% | -18.9% | AMPH higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.